Promising drug combo aims to halt smoldering myeloma before it strikes
NCT ID NCT02960555
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study tests a drug called isatuximab, given alone or with lenalidomide, in 61 people with high risk smoldering multiple myeloma. The goal is to see if the treatment can shrink or control the cancer cells before they turn into active myeloma. Participants receive the drugs intravenously or orally, and doctors monitor their response and side effects closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.